Corcept Therapeutics Incorporated
CORT
$69.57
$0.751.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 716.08M | 685.45M | 675.04M | 628.56M | 569.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 716.08M | 685.45M | 675.04M | 628.56M | 569.61M |
| Cost of Revenue | 11.66M | 10.75M | 10.38M | 9.30M | 8.08M |
| Gross Profit | 704.42M | 674.70M | 664.66M | 619.25M | 561.53M |
| SG&A Expenses | 351.63M | 314.71M | 280.32M | 244.10M | 215.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 614.13M | 574.58M | 537.59M | 484.70M | 441.17M |
| Operating Income | 101.95M | 110.87M | 137.45M | 143.86M | 128.44M |
| Income Before Tax | 126.21M | 136.12M | 161.49M | 166.34M | 149.78M |
| Income Tax Expenses | -7.44M | 2.12M | 20.28M | 24.52M | 23.80M |
| Earnings from Continuing Operations | 133.66 | 133.99 | 141.21 | 141.82 | 125.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 133.66M | 133.99M | 141.21M | 141.82M | 125.98M |
| EBIT | 101.95M | 110.87M | 137.45M | 143.86M | 128.44M |
| EBITDA | 103.12M | 111.83M | 138.25M | 144.59M | 129.08M |
| EPS Basic | 1.27 | 1.28 | 1.35 | 1.36 | 1.22 |
| Normalized Basic EPS | 0.76 | 0.82 | 0.98 | 1.01 | 0.92 |
| EPS Diluted | 1.13 | 1.16 | 1.24 | 1.26 | 1.13 |
| Normalized Diluted EPS | 0.67 | 0.74 | 0.90 | 0.93 | 0.85 |
| Average Basic Shares Outstanding | 415.23M | 414.24M | 412.92M | 411.74M | 410.38M |
| Average Diluted Shares Outstanding | 472.49M | 463.25M | 453.34M | 445.77M | 443.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |